Key Points
- Nasus Pharma CEO Dan Benjamin Teleman bought 2,900 shares on April 22 at an average price of $3.76, bringing his total to 156,991 shares—a 1.88% increase in his ownership (total value about $590,286).
- Shares are under pressure, trading down 12.6% and opening at $3.40, with a 52‑week range of $1.98–$9.99 and a 50‑day simple moving average of $3.60.
- Analysts remain upbeat: Citizens Jmp trimmed its target to $18 but kept a "market outperform" rating, and the consensus rating is "Buy" with an average target of $18.
Nasus Pharma Ltd. (NYSEAMERICAN:NSRX - Get Free Report) CEO Dan Benjamin Teleman bought 2,900 shares of the firm's stock in a transaction dated Wednesday, April 22nd. The shares were acquired at an average cost of $3.76 per share, with a total value of $10,904.00. Following the completion of the transaction, the chief executive officer owned 156,991 shares of the company's stock, valued at $590,286.16. This represents a 1.88% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.
Nasus Pharma Trading Down 12.6%
Shares of NYSEAMERICAN NSRX opened at $3.40 on Friday. Nasus Pharma Ltd. has a fifty-two week low of $1.98 and a fifty-two week high of $9.99. The company has a 50-day simple moving average of $3.60.
Analyst Upgrades and Downgrades
Separately, Citizens Jmp dropped their target price on Nasus Pharma from $19.00 to $18.00 and set a "market outperform" rating on the stock in a report on Thursday, March 26th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Nasus Pharma presently has a consensus rating of "Buy" and an average target price of $18.00.
Read Our Latest Stock Report on NSRX
About Nasus Pharma
(
Get Free Report)
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
